BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Palace J, Wingerchuk DM, Fujihara K, Berthele A, Oreja-Guevara C, Kim HJ, Nakashima I, Levy M, Terzi M, Totolyan N, Viswanathan S, Wang KC, Pace A, Yountz M, Miller L, Armstrong R, Pittock S; PREVENT Study Group. Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial. Mult Scler Relat Disord 2021;47:102641. [PMID: 33310418 DOI: 10.1016/j.msard.2020.102641] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Kim HJ, Nakashima I, Viswanathan S, Wang KC, Shang S, Miller L, Yountz M, Wingerchuk DM, Pittock SJ, Levy M, Berthele A, Totolyan N, Palace J, Barnett MH, Fujihara K; PREVENT Study Group. Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: A subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension. Mult Scler Relat Disord 2021;50:102849. [PMID: 33676197 DOI: 10.1016/j.msard.2021.102849] [Reference Citation Analysis]
2 Liu C, Shi M, Zhu M, Chu F, Jin T, Zhu J. Comparisons of clinical phenotype, radiological and laboratory features, and therapy of neuromyelitis optica spectrum disorder by regions: update and challenges. Autoimmun Rev 2021;:102921. [PMID: 34384938 DOI: 10.1016/j.autrev.2021.102921] [Reference Citation Analysis]
3 McCombe JA, Pittock SJ. Anti-complement Agents for Autoimmune Neurological Disease. Neurotherapeutics 2022. [PMID: 35553024 DOI: 10.1007/s13311-022-01223-w] [Reference Citation Analysis]
4 Wingerchuk DM, Fujihara K, Palace J, Berthele A, Levy M, Kim HJ, Nakashima I, Oreja-Guevara C, Wang KC, Miller L, Shang S, Sabatella G, Yountz M, Pittock SJ; PREVENT Study Group. Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD. Ann Neurol 2021;89:1088-98. [PMID: 33586143 DOI: 10.1002/ana.26049] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
5 Giglhuber K, Berthele A. Adverse Events in NMOSD Therapy. IJMS 2022;23:4154. [DOI: 10.3390/ijms23084154] [Reference Citation Analysis]
6 Romeo AR. Recent advances in the treatment of neuromyelitis optica spectrum disorders. Curr Opin Rheumatol 2021;33:233-9. [PMID: 33741809 DOI: 10.1097/BOR.0000000000000791] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Mader S, Brimberg L, Vo A, Strohl JJ, Crawford JM, Bonnin A, Carrión J, Campbell D, Huerta TS, La Bella A, Berlin R, Dewey SL, Hellman M, Eidelberg D, Dujmovic I, Drulovic J, Bennett JL, Volpe BT, Huerta PT, Diamond B. In utero exposure to maternal anti-aquaporin-4 antibodies alters brain vasculature and neural dynamics in male mouse offspring. Sci Transl Med 2022;14:eabe9726. [PMID: 35442708 DOI: 10.1126/scitranslmed.abe9726] [Reference Citation Analysis]
8 Simaniv TO, Kochergin IA, Zakharova MN, Korobko DS, Zaslavskii LG, Zelenova OV, Abramov SI. [Clinical and epidemiological aspects of neuromyelitis optic spectrum diseases in the russian population]. Zh Nevrol Psikhiatr Im S S Korsakova 2021;121:96-103. [PMID: 34460164 DOI: 10.17116/jnevro202112107196] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]